サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1452546

北米の急性膵炎市場の2030年予測- 地域別分析- 製品別、原因別、エンドユーザー別

North America Acute Pancreatitis Market Forecast to 2030 - Regional Analysis - by Offerings, Causes, and End User
出版日: | 発行: The Insight Partners | ページ情報: 英文 94 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
北米の急性膵炎市場の2030年予測- 地域別分析- 製品別、原因別、エンドユーザー別
出版日: 2024年01月03日
発行: The Insight Partners
ページ情報: 英文 94 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米の急性膵炎市場は、2022年に32億963万米ドルと評価され、2030年には50億71万米ドルに達すると予測され、2022年から2030年までのCAGRは5.7%で成長すると予測されています。

急性膵炎による膵臓がん患者の増加が北米急性膵炎市場を後押し

膵臓がんは、欧米諸国におけるがん関連死亡原因の第4位です。米国がん協会（American Cancer Society）のCancer Facts & Figures 2022によると、膵臓がんの死亡率は2030年までに米国におけるがんによる死亡率の中で2番目に高くなると予測されています。腫瘍が切除可能な早期に発見されないと進行する可能性が高いです。2021年に国立医療図書館に掲載された論文によると、診断時に切除可能な膵臓腫瘍はわずか約15％で、5年生存率は8％に制限されます。しかし、初期症状がないため、これらの腫瘍の診断が悪く、切除可能性が低いです。急性膵炎は膵がんの初期症状であるため、膵がんを引き起こす可能性があり、急性膵炎入院患者のほぼ1％が膵がんと診断されます。これらの患者が急性膵炎と診断されてから膵がんと診断されるまでには数ヵ月を要するが、最初の誤診のために診断がより遅れ、回復の妨げになる患者もいます。急性膵炎の再発は慢性膵炎につながり、膵がんのリスクをさらに高める可能性があります。

国立糖尿病・消化器・腎臓病研究所によると、急性膵炎は27万5,000人の入院につながり、米国ではこの数が増加しています。米国における急性膵炎の35～40％は胆石が原因であり、飲酒は30％の原因です。膵炎は通常、入院患者の80％が軽症で、ほとんどが入院後数日以内に退院できます。急性膵炎の死亡率は～2％で、再発率は0.6％～5.6％です。アルコール関連膵炎は再発率が最も高いです。2022年にLancet Gastroenterology Hepatologyに掲載された論文によると、急性膵炎の世界のプール発症率は年間10万人当たり34例です。北米は10万人当たり年間58.2例（米国は10万人当たり年間58.2例）、欧州はスウェーデンが10万人当たり24.7例、デンマークが10万人当たり15.0例です。

消化酵素が膵管内腔ではなく膵間質に放出される急性膵炎は、腫瘍による膵管閉塞のために膵がんの早期指標となる可能性があります。急性膵炎は痛みを伴うため、患者はより早く医療機関を受診し、早期がん診断につながる可能性があります。したがって、急性膵炎による膵臓がんの症例の増加は、北米急性膵炎市場の成長を後押しします。

北米の急性膵炎市場概要

北米の急性膵炎市場は米国、カナダ、メキシコに区分されます。2022年には、米国がこの地域で最大の市場シェアを占めており、予測期間中もその優位性が続くと予測されています。北米の急性膵炎市場は、胆石症例の増加やアルコールの過剰摂取による急性膵炎の負担増により成長が見込まれています。また、医療施設における技術進歩の増加に伴い、北米の市場は予測期間中に成長すると予想されます。

北米の急性膵炎市場の収益と2030年までの予測（US$Mn）

北米の急性膵炎市場セグメンテーション

北米の急性膵炎市場は、製品、原因、エンドユーザー、国別に区分されます。

製品物に基づき、北米の急性膵炎市場は投薬、診断、その他にセグメント化されます。診断セグメントが2022年に最大の市場シェアを占めました。

原因に基づき、北米の急性膵炎市場は胆石、アルコール中毒、遺伝性疾患、感染症、その他に区分されます。胆石セグメントが2022年に最大の市場シェアを占めました。

エンドユーザー別に見ると、北米の急性膵炎市場は病院、診断ラボ、外来手術センター、その他に分けられます。病院セグメントが2022年に最大の市場シェアを占めました。

国別では、北米の急性膵炎市場は米国、カナダ、メキシコに区分されます。米国が2022年の北米急性膵炎市場シェアを独占しました。

Abbott Laboratories、Baxter International Inc、Boston Scientific Corp、Dynavax Technologies Corp、Fresenius Kabi AG、GE HealthCare Technologies Inc、Koninklijke Philips NV、Medtronic Plc、Samsung Healthcareは、北米急性膵炎市場で事業を展開している大手企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブ・サマリー

  • 主要洞察
  • 北米の急性膵炎市場：国別

第3章 調査方法

  • 調査範囲
  • 二次調査
  • 一次調査

第4章 北米の急性膵炎市場展望

第5章 北米急性膵炎市場-主要産業力学

  • 主要市場の促進要因
    • 急性膵炎による膵がん患者の増加
    • 急性膵炎後の糖尿病罹患率の上昇
  • 主要市場阻害要因
    • 膵炎と膵がん治療の副作用
  • 主要市場機会
    • 急性膵炎に関する研究開発活動と啓発プログラムの増加
  • 今後の動向
    • 特定の急性膵炎治療の進歩
  • 影響分析

第6章 急性膵炎市場-北米市場分析

  • 北米の急性膵炎市場売上実績、2022～2030年

第7章 北米急性膵炎市場-2030年までの収益と予測：製品別

  • イントロダクション
  • 北米の急性膵炎市場：売上高シェア（2022年・2030年）：製品別
  • 薬
  • 診断薬
  • その他

第8章 北米の急性膵炎市場-2030年までの収益と予測：原因別

  • イントロダクション
  • 北米の急性膵炎市場：売上高シェア（2022年・2030年）：原因別
  • 胆石症
  • アルコール中毒
  • 遺伝性疾患
  • 感染症
  • その他

第9章 北米の急性膵炎市場-売上高と2030年までの予測：エンドユーザー別

  • イントロダクション
  • 北米の急性膵炎市場：売上高シェア（2022年・2030年）：エンドユーザー別
  • 病院
  • 診断ラボ
  • 外来手術センター
  • その他

第10章 北米の急性膵炎市場：国別分析

      • 北米の急性膵炎市場：国別
      • 米国
      • カナダ
      • メキシコ

第11章 北米の急性膵炎市場-産業展望

  • イントロダクション
  • 北米急性膵炎市場における成長戦略
  • 無機的成長戦略
  • 有機的成長戦略

第12章 企業プロファイル

  • Abbott Laboratories
  • GE HealthCare Technologies Inc
  • Samsung Healthcare
  • Koninklijke Philips NV
  • Baxter International Inc
  • Dynavax Technologies Corp
  • Medtronic Plc
  • Boston Scientific Corp
  • Fresenius Kabi AG

第13章 付録

図表

List Of Tables

  • Table 1. North America Acute Pancreatitis Market Segmentation
  • Table 2. North America Acute Pancreatitis Market, by Medications - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. North America Acute Pancreatitis Market, by Diagnosis - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. US: North America Acute Pancreatitis Market, by Offerings - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. US: North America Acute Pancreatitis Market, For Medications by Offerings - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. US: North America Acute Pancreatitis Market, For Diagnosis by Offerings - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. US: North America Acute Pancreatitis Market, by Causes - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. US: North America Acute Pancreatitis Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. Canada: North America Acute Pancreatitis Market, by Offerings - Revenue and Forecast to 2030 (US$ Million)
  • Table 10. Canada: North America Acute Pancreatitis Market, For Medications by Offerings - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Canada: North America Acute Pancreatitis Market, For Diagnosis by Offerings - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Canada: North America Acute Pancreatitis Market, by Causes - Revenue and Forecast to 2030 (US$ Million)
  • Table 13. Canada: North America Acute Pancreatitis Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 14. Mexico: North America Acute Pancreatitis Market, by Offerings - Revenue and Forecast to 2030 (US$ Million)
  • Table 15. Mexico: North America Acute Pancreatitis Market, For Medications by Offerings - Revenue and Forecast to 2030 (US$ Million)
  • Table 16. Mexico: North America Acute Pancreatitis Market, For Diagnosis by Offerings - Revenue and Forecast to 2030 (US$ Million)
  • Table 17. Mexico: North America Acute Pancreatitis Market, by Causes - Revenue and Forecast to 2030 (US$ Million)
  • Table 18. Mexico: North America Acute Pancreatitis Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 19. Recent Inorganic Growth Strategies in the North America Acute Pancreatitis Market
  • Table 20. Recent Organic Growth Strategies in the North America Acute Pancreatitis Market
  • Table 21. Glossary of Terms, North America Acute Pancreatitis Market

List Of Figures

  • Figure 1. North America Acute Pancreatitis Market Segmentation, By Country
  • Figure 2. North America Acute Pancreatitis Market - Key Industry Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. North America Acute Pancreatitis Market Revenue (US$ Mn), 2022 - 2030
  • Figure 5. North America Acute Pancreatitis Market Revenue Share, by Offerings, 2022 & 2030 (%)
  • Figure 6. Medications: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Diagnosis: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. North America Acute Pancreatitis Market Revenue Share, by Causes 2022 & 2030 (%)
  • Figure 10. Gallstones: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Alcoholism: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Genetic Disorders: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Infections: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Others: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. North America Acute Pancreatitis Market Revenue Share, by End User, 2022 & 2030 (%)
  • Figure 16. Hospitals: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Diagnostic Laboratories: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Ambulatory Surgical Centers: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Others: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. North America Acute Pancreatitis Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 21. North America Acute Pancreatitis Market, By Key Countries, 2022 and 2030 (%)
  • Figure 22. US: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 23. Canada: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 24. Mexico: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 25. Growth Strategies in the North America Acute Pancreatitis Market
目次
Product Code: BMIRE00029237

The North America acute pancreatitis market was valued at US$ 3,209.63 million in 2022 and is expected to reach US$ 5,000.71 million by 2030; it is estimated to grow at a CAGR of 5.7% from 2022 to 2030.

Rise in Pancreatic Cancer Cases Due to Acute Pancreatitis Fuels the North America Acute Pancreatitis Market

Pancreatic cancer is the fourth leading cause of cancer-related mortality in Western countries. According to the American Cancer Society, Cancer Facts & Figures 2022, the mortality rate of pancreatic cancer is predicted to be the second highest among all cancer-led mortality rates in the US by 2030. It is more likely to progress if not detected early when the tumor is resectable. According to an article published in the National Library of Medicine in 2021, only ~15% of pancreatic tumors are resectable at diagnosis, limiting five-year survival to 8%. However, the lack of early symptoms results in poor diagnosis and low resectability of these tumors. Acute pancreatitis may cause pancreatic cancer as it is an early symptom of pancreatic cancer, nearly 1% of acute pancreatitis admissions result in pancreatic cancer diagnoses. It takes several months for these patients to be diagnosed with pancreatic cancer after acute pancreatitis is diagnosed, but some suffer longer diagnostic delays due to initial misdiagnosis, which may hinder their recovery. Recurrent occurrence of acute pancreatitis leads to chronic pancreatitis, which may further increase the risk of pancreatic cancer.

According to the National Institute of Diabetes and Digestive and Kidney Diseases, acute pancreatitis leads to ~275,000 hospital admissions each year, and this number has been increasing in the US. ~35-40% of acute pancreatitis cases in the US are due to gallstones, while alcohol consumption is the cause of 30% of cases. Pancreatitis is usually mild in 80% of patients who are admitted, and most can be discharged within a few days of their hospitalization. Acute pancreatitis is associated with a mortality rate of ~2% and has a relapse rate between 0.6% and 5.6%. Alcohol-related pancreatitis has the highest rate of relapse. According to an article published in Lancet Gastroenterology Hepatology in 2022, the global pooled incidence of acute pancreatitis is 34 cases per 100,000 per year. North America has 58.2 cases per 100,000 people per year (the US has 58.2 cases per 100,000 people per year) while Europe has 24.7 and 15.0 cases per 100,000 people in Sweden and Denmark, respectively.

Acute pancreatitis, which causes the release of digestive enzymes into the pancreatic interstitial space instead of the pancreatic duct lumen, could be an early indicator of pancreatic cancer due to tumor obstruction of the pancreatic duct. Acute pancreatitis is a painful condition, so patients seek medical care sooner, which could lead to an early cancer diagnosis. Therefore, rising cases of pancreatic cancer due to acute pancreatitis boosts the growth of the North America acute pancreatitis market.

North America Acute Pancreatitis Market Overview

The North America acute pancreatitis market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share in this region and is expected to continue its dominance during the forecast period. the North America acute pancreatitis market in North America is expected to grow due to the increasing burden of acute pancreatitis due to increase in cases of gallstones and excessive consumption of alcohol. Also, with an increase in technological advancement in healthcare facilities, the market in North America is expected to grow during the forecast period.

North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)

North America Acute Pancreatitis Market Segmentation

The North America acute pancreatitis market is segmented offerings, causes, end user, and country.

Based on offerings, the North America acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held the largest market share in 2022.

Based on causes, the North America acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held the largest market share in 2022.

Based on end user, the North America acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held the largest market share in 2022.

Based on country, the North America acute pancreatitis market is segmented into the US, Canada, and Mexico. The US dominated the North America acute pancreatitis market share in 2022.

Abbott Laboratories, Baxter International Inc, Boston Scientific Corp, Dynavax Technologies Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare are some of the leading companies operating in the North America acute pancreatitis market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 North America Acute Pancreatitis Market, by Country (US$ Million)

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Acute Pancreatitis Market Landscape

  • 4.1 Overview

5. North America Acute Pancreatitis Market - Key Industry Dynamics

  • 5.1 Key Market Drivers
    • 5.1.1 Rise in Pancreatic Cancer Cases Due to Acute Pancreatitis
    • 5.1.2 Rising Incidence of Diabetes Following Acute Pancreatitis
  • 5.2 Key Market Restraints
    • 5.2.1 Side Effects of Pancreatitis and Pancreatic Cancer Treatments
  • 5.3 Key Market Opportunities
    • 5.3.1 Upsurge in Number of R&D Activities and Awareness Programs on Acute Pancreatitis
  • 5.4 Future Trends
    • 5.4.1 Advancements in Specific Acute Pancreatitis Treatments
  • 5.5 Impact Analysis:

6. Acute Pancreatitis Market - North America Market Analysis

  • 6.1 North America Acute Pancreatitis Market Revenue (US$ Mn), 2022 - 2030

7. North America Acute Pancreatitis Market - Revenue and Forecast to 2030 - by Offerings

  • 7.1 Overview
  • 7.2 North America Acute Pancreatitis Market Revenue Share, by Offerings, 2022 & 2030 (%)
  • 7.3 Medications
    • 7.3.1 Overview
    • 7.3.2 Medications: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.3.2.1 North America Acute Pancreatitis Market, by Medications, 2020-2030 (US$ Million)
  • 7.4 Diagnosis
    • 7.4.1 Overview
    • 7.4.2 Diagnosis: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.4.2.1 North America Acute Pancreatitis Market, by Diagnosis, 2020-2030 (US$ Million)
  • 7.5 Others
    • 7.5.1 Overview
    • 7.5.2 Others: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Acute Pancreatitis Market - Revenue and Forecast to 2030 - by Causes

  • 8.1 Overview
  • 8.2 North America Acute Pancreatitis Market Revenue Share, by Causes 2022 & 2030 (%)
  • 8.3 Gallstones
    • 8.3.1 Overview
    • 8.3.2 Gallstones: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Alcoholism
    • 8.4.1 Overview
    • 8.4.2 Alcoholism: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Genetic Disorders
    • 8.5.1 Overview
    • 8.5.2 Genetic Disorders: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Infections
    • 8.6.1 Overview
    • 8.6.2 Infections: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.7 Others
    • 8.7.1 Overview
    • 8.7.2 Others: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Acute Pancreatitis Market - Revenue and Forecast to 2030 - by End User

  • 9.1 Overview
  • 9.2 North America Acute Pancreatitis Market Revenue Share, by End User, 2022 & 2030 (%)
  • 9.3 Hospitals
    • 9.3.1 Overview
    • 9.3.2 Hospitals: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Diagnostic Laboratories
    • 9.4.1 Overview
    • 9.4.2 Diagnostic Laboratories: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Ambulatory Surgical Centers
    • 9.5.1 Overview
    • 9.5.2 Ambulatory Surgical Centers: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.6 Others
    • 9.6.1 Overview
    • 9.6.2 Others: North America Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Acute Pancreatitis Market - Country Analysis

  • 10.1 Overview
      • 10.1.1.1 North America Acute Pancreatitis Market, by Country
      • 10.1.1.2 US
        • 10.1.1.2.1 Overview
        • 10.1.1.2.2 US: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.2.3 US: North America Acute Pancreatitis Market, by Offerings, 2020-2030 (US$ Million)
        • 10.1.1.2.3.1 US: North America Acute Pancreatitis Market, For Medications by Offerings, 2020-2030 (US$ Million)
        • 10.1.1.2.3.2 US: North America Acute Pancreatitis Market, For Diagnosis by Offerings, 2020-2030 (US$ Million)
        • 10.1.1.2.4 US: North America Acute Pancreatitis Market, by Causes, 2020-2030 (US$ Million)
        • 10.1.1.2.5 US: North America Acute Pancreatitis Market, by End User, 2020-2030 (US$ Million)
      • 10.1.1.3 Canada
        • 10.1.1.3.1 Overview
        • 10.1.1.3.2 Canada: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.3.3 Canada: North America Acute Pancreatitis Market, by Offerings, 2020-2030 (US$ Million)
        • 10.1.1.3.3.1 Canada: North America Acute Pancreatitis Market, For Medications by Offerings, 2020-2030 (US$ Million)
        • 10.1.1.3.3.2 Canada: North America Acute Pancreatitis Market, For Diagnosis by Offerings, 2020-2030 (US$ Million)
        • 10.1.1.3.4 Canada: North America Acute Pancreatitis Market, by Causes, 2020-2030 (US$ Million)
        • 10.1.1.3.5 Canada: North America Acute Pancreatitis Market, by End User, 2020-2030 (US$ Million)
      • 10.1.1.4 Mexico
        • 10.1.1.4.1 Overview
        • 10.1.1.4.2 Mexico: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.1.4.3 Mexico: North America Acute Pancreatitis Market, by Offerings, 2020-2030 (US$ Million)
        • 10.1.1.4.3.1 Mexico: North America Acute Pancreatitis Market, For Medications by Offerings, 2020-2030 (US$ Million)
        • 10.1.1.4.3.2 Mexico: North America Acute Pancreatitis Market, For Diagnosis by Offerings, 2020-2030 (US$ Million)
        • 10.1.1.4.4 Mexico: North America Acute Pancreatitis Market, by Causes, 2020-2030 (US$ Million)
        • 10.1.1.4.5 Mexico: North America Acute Pancreatitis Market, by End User, 2020-2030 (US$ Million)

11. North America Acute Pancreatitis Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the North America Acute Pancreatitis Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Abbott Laboratories
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 GE HealthCare Technologies Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Samsung Healthcare
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Koninklijke Philips NV
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Baxter International Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Dynavax Technologies Corp
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Medtronic Plc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Boston Scientific Corp
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Fresenius Kabi AG
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms